Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Gains from Investment Securities (2016 - 2025)

Teva Pharmaceutical Industries (TEVJF) has disclosed Gains from Investment Securities for 16 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$2.0 million, compared with a TTM value of -$4.0 million through Dec 2025, down 100.0%, and an annual FY2025 reading of -$5.0 million, down 150.0% over the prior year.
  • Gains from Investment Securities was -$2.0 million for Q3 2025 at Teva Pharmaceutical Industries, roughly flat from -$2.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $547.0 million in Q4 2022 and bottomed at -$6.0 million in Q3 2022.
  • Average Gains from Investment Securities over 5 years is $86.7 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Gains from Investment Securities crashed 106.67% in 2021, then surged 116.67% in 2023.
  • Year by year, Gains from Investment Securities stood at $498.0 million in 2021, then rose by 9.84% to $547.0 million in 2022, then tumbled by 100.18% to -$1.0 million in 2023, then plummeted by 100.0% to -$2.0 million in 2024, then changed by 0.0% to -$2.0 million in 2025.
  • Business Quant data shows Gains from Investment Securities for TEVJF at -$2.0 million in Q3 2025, -$2.0 million in Q4 2024, and -$1.0 million in Q4 2023.